Under the National AIDS Control Programme (NACP), the Prevention of Parent-to-Child Transmission (PPTCT) programme uses a specific antiretroviral regimen for all HIV-positive pregnant women regardless of CD4 count or clinical stage. The current WHO-option regimen adopted by NACO for PPTCT is:
- A Single-dose nevirapine during labour
- B Zidovudine monotherapy from 14 weeks of gestation
- C Triple drug ART (TDF + 3TC + EFV) started immediately and continued lifelong ✓
- D Dual therapy with zidovudine and lamividine for 6 weeks postpartum only
Correct answer: C. Triple drug ART (TDF + 3TC + EFV) started immediately and continued lifelong
Explanation
NACO adopted the WHO Option B+ approach: all HIV-positive pregnant women receive lifelong triple-drug ART (TDF + 3TC + EFV) regardless of CD4 count or clinical stage. Single-dose nevirapine and zidovudine monotherapy are outdated strategies no longer recommended.
Reference: NACO Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents, 2021 ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.